Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure
Open Access
- 1 August 2020
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 5 (8) , 948-951
Abstract
Sodium-glucose cotransporter 2 inhibitor (SGLT2-i) therapy was initially directed toward the management of type 2 diabetes. The first cardiovascular clinical outcome trial of SGLT2-i therapy, the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME), demonstrated an unexpected and substantial reduction in all-cause mortality, cardiovascular death, and heart failure (HF) hospitalizations among patients with type 2 diabetes.1 Significant reductions in HF hospitalizations were also demonstrated with the SGLT2-i canagliflozin in the Canagliflozin Cardiovascular Assessment Study2 and with dapagliflozin in the Dapagliflozin Effect on Cardiovascular Events trial,3 thus confirming the EMPA-REG OUTCOME findings. Sodium-glucose cotransporter 2 inhibitors are now established as among the most effective therapies to prevent HF in patients with type 2 diabetes.4Keywords
This publication has 17 references indexed in Scilit:
- Medical Therapy for Heart Failure With Reduced Ejection FractionJACC, 2018
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine, 2017
- New York Heart Association Functional Class, Qrs Duration, and Survival in Heart Failure with Reduced Ejection Fraction: Implications for Cardiac Resychronization TherapyEuropean Journal of Heart Failure, 2016
- Healthy Lifestyle and Risk of Heart FailureCirculation: Heart Failure, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- 2013 ACCF/AHA Guideline for the Management of Heart FailureJACC, 2013
- Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection FractionCirculation, 2012
- Potential impact of optimal implementation of evidence-based heart failure therapies on mortalityAmerican Heart Journal, 2011
- Improving Evidence-Based Care for Heart Failure in Outpatient Cardiology PracticesCirculation, 2010
- Potential survival gains in the treatment of myocardial infarctionHeart, 2009